MAPLIGHT THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1 CLINICAL TRIAL FOR ML-007/PAC, UNDER DEVELOPMENT FOR SCHIZOPHRENIA AND ALZHEIMER’S DISEASE PSYCHOSIS

Study to evaluate safety and tolerability of extended-release fixed dose combination ML-007/PAC with precision-matched release kinetics in advance of planned Phase 2 clinical trials ML-007/PAC dosing regimens to be assessed in healthy non-elderly and elderly adults SAN FRANCISCO and…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks